(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 49.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Zymeworks's revenue in 2025 is $62,199,000.On average, 5 Wall Street analysts forecast ZYME's revenue for 2025 to be $6,289,482,409, with the lowest ZYME revenue forecast at $3,719,386,404, and the highest ZYME revenue forecast at $8,367,930,634. On average, 4 Wall Street analysts forecast ZYME's revenue for 2026 to be $15,161,458,778, with the lowest ZYME revenue forecast at $8,237,752,110, and the highest ZYME revenue forecast at $21,424,354,462.
In 2027, ZYME is forecast to generate $11,586,784,056 in revenue, with the lowest revenue forecast at $5,785,712,184 and the highest revenue forecast at $14,512,494,728.